Evidence & Research Status
When the FDA's Pharmacy Compounding Advisory Committee met on July 23–24, 2026, it put recovery peptide evidence on the record in a way the field had not seen before. The committee reviewed BPC-157…
Evidence Level reflects the general state of published research for this compound category and is not a claim about the safety, efficacy, or approval status of any product sold on this site. All compounds are offered strictly for research use.
When the FDA’s Pharmacy Compounding Advisory Committee met on July 23–24, 2026, it put recovery peptide evidence on the record in a way the field had not seen before. The committee reviewed BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax, and agency scientists published their read of the underlying human data for each one.
For researchers evaluating these compounds, the committee record is more useful than the vote itself. It is a structured, publicly documented assessment of how much human evidence exists for each compound — and how much does not.
What the committee actually voted on
An FDA advisory committee voted in favor of six peptides for the Section 503A Bulk Drug Substances List. BPC-157, KPV and TB-500 passed 8–6 with one abstention. MOTS-c passed 7–5 with two abstentions. Notably, the committee’s recommendations ran against the position of the agency’s own reviewing scientists, who had advised against all seven substances under review.
These were not drug approvals. A recommendation to the 503A list is a recommendation about eligibility for patient-specific compounding under federal and state conditions — it is not a finding of safety or efficacy, and it does not change the regulatory status of material sold for laboratory research. That distinction matters, and it is frequently collapsed in secondary coverage.
The vote followed an earlier step: on April 22, 2026, the FDA removed twelve peptide bulk drug substances from Category 2, the designation that had flagged them as posing significant safety risks for compounding. Removal from Category 2 did not place them on the 503A list; it left them in an interim position pending the committee review and subsequent agency action.
The evidence gradient the review documented
The most substantive part of the record is the disparity in human data across the four recovery-associated compounds. Reviewers did not describe a uniform evidence base — they described a steep gradient.
| Compound | Human data characterized in review | Predominant literature type |
|---|---|---|
| BPC-157 | Little human evidence | Extensive rodent and in vitro work |
| TB-500 | No direct human administration studies identified | Preclinical models |
| KPV | No human exposure data identified | Cell and animal models |
| MOTS-c | Human physiology research plus one registered clinical trial without posted outcomes | Cell, animal, and observational human physiology |
Read carefully, this is a map of where the open questions are. TB-500 and KPV sit at one end, with the committee record indicating no identified direct human administration or exposure studies. MOTS-c sits at the other, with observational human physiology work and a registered trial whose outcomes had not been posted at the time of review. BPC-157 occupies a middle position that is easy to misread: a large preclinical literature is not the same thing as a human evidence base, and volume of publication should not be mistaken for depth of human characterization.
Why the preclinical-to-human gap persists
Several structural factors explain the pattern. Peptides in this class are largely off-patent or unpatentable in their native sequences, which removes the commercial incentive that normally funds Phase 1 through Phase 3 programs. Short plasma half-lives and questions about oral bioavailability complicate study design. And because much of the existing work originated in academic laboratories studying mechanism rather than in sponsors seeking marketing authorization, endpoints were chosen to answer mechanistic questions, not regulatory ones.
The result is a literature that is genuinely informative about signaling pathways — angiogenic and cytoprotective pathways for BPC-157, actin sequestration for TB-500, melanocortin-linked anti-inflammatory signaling for KPV, AMPK activation for MOTS-c — and largely silent on human pharmacokinetics.
Open questions for researchers
- Pharmacokinetics. For TB-500 and KPV especially, basic human absorption, distribution and clearance parameters were not established in the reviewed literature.
- Analytical identity. Reviewers repeatedly raised characterization and purity of bulk material as a distinct question from the pharmacology, which is why independent third-party analysis of any research material remains the practical baseline.
- Translation of mechanism. Whether the pathway activity observed in rodent injury models corresponds to measurable effects in human tissue remains, per the record, unresolved.
- MOTS-c outcome reporting. The registered trial noted in the review had not posted results; its eventual readout is the single most informative near-term data point in this group.
Where this leaves the field
The committee’s recommendations now go to the FDA, which is not bound by them and has not issued final action. Until it does, the practical situation is unchanged for laboratory-supplied material: these compounds remain research chemicals, not approved drugs, and the honest summary of recovery peptide evidence is that mechanism is comparatively well described while human data is thin to absent.
For anyone building a literature review in this area, the committee’s own background materials — available through the FDA’s PCAC meeting page — are a better starting point than most secondary summaries, because they cite the primary studies directly and state plainly where studies were not found. Additional regulatory context is available via the FDA Law Blog’s analysis of the 2026 peptide docket.
All compounds referenced in this article are available for research use only. This article is provided for informational and educational purposes. No therapeutic claims are made or implied.